Flomics

Executive Summary

Flomics is a Barcelona-based biotechnology company developing a next-generation liquid biopsy platform for multi-cancer early detection. The company leverages cell-free RNA (cfRNA) sequencing and machine learning to identify disease-specific expression patterns from a standard blood draw, aiming to detect cancer before symptoms appear. Flomics has been operating since 2015 and is privately held, with no disclosed funding rounds or valuation. Its approach focuses on a non-invasive blood test that could transform cancer screening by covering multiple cancer types simultaneously. While the company has not publicly announced clinical trial results or partnerships, its platform aligns with the growing interest in liquid biopsy and early detection. The technology is still in development, and key milestones such as validation studies, regulatory submissions, or commercial launch are expected in the coming years. Flomics operates in a competitive landscape but could differentiate through its cfRNA-based approach and focus on multi-cancer detection.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation data for multi-cancer detection50% success
• Q2 2026Series A or B financing round to advance clinical trials60% success
• Q3 2026Strategic partnership with a diagnostic or pharmaceutical company40% success